Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Perspective Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Perspective Therapeutics, Inc.

CATX

Perspective Therapeutics, Inc.

About Perspective Therapeutics, Inc.

Perspective Therapeutics is a biopharmaceutical company specializing in targeted alpha radiopharmaceuticals for cancer treatment. Its core focus is developing precision therapies using proprietary Lead-212 (212Pb) and Lead-203 (203Pb) isotopes, combined with specialized targeting peptides for cancers like neuroendocrine tumors and melanoma. The company leverages theranostic diagnostics, scalable manufacturing, and a broad pipeline to deliver personalized, effective cancer treatments with minimized toxicity.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Perspective Therapeutics, Inc.

1
1
Perspective Therapeutics, Inc. Perspective Therapeutics Reports Q1 2026 Financial Results with Increased Assets and Operating Loss

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
Perspective Therapeutics, Inc. Perspective Therapeutics Reports Financial Results and Operational Developments for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Perspective Therapeutics, Inc. Perspective Therapeutics Reports Significant Revenue Decline and Increased Losses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Perspective Therapeutics, Inc. Perspective Therapeutics Reports Increased Operating Losses and Declining Grant Revenue in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Perspective Therapeutics, Inc. Perspective Therapeutics Reports Q1 2025 Financial Results with Increased Revenue and Operating Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Perspective Therapeutics, Inc. Perspective Therapeutics Reports $79.3 Million Net Loss for 2024, Highlights Key Developments

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Perspective Therapeutics, Inc. Perspective Therapeutics Reports Significant Financial Growth and Cash Flow Improvement

Via official filing (AI summary) | over 1 year ago | 0 comments